Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05867589
Status:
RECRUITING
Last Update Posted:
2023-05-22
First Post:
2023-05-11
Brief Title:
Study of Novel PET Tracer Gallium 68Ga Fluorine 18F -FAPI-04 in the Diagnosis of Cardiovascular Diseases
Sponsor:
Nanjing First Hospital Nanjing Medical University
Organization:
Nanjing First Hospital Nanjing Medical University
Study Overview
Official Title:
Study of Novel PET Tracer Gallium 68Ga Fluorine 18F -FAPI-04 in the Diagnosis of Cardiovascular Diseases
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety of fibroblast activating protein receptor imaging agent 68Ga Fluorine 18F -fibroblast activating protein inhibitor 68Ga18F-FAPI-04 in clinical application and to verify its effectiveness in the diagnosis of cardiovascular diseases
Detailed Description:
The implementation of this project will promote the research of PET-MRI molecular imaging using the new nuclide imaging with the target of FAP combined with the MRI T1 mapping and ECV measurement technology realize the fusion of nuclear medicine and magnetic resonance technology in a real sense dynamically monitor the occurrence and development of myocardial fibrosis in heart failure at an early stage and establish a complete set of myocardial fibrosis imaging programs To provide an important basis for the exploration of anti-fibrosis therapy in heart failure and accelerate the pace of clinical transformation of this protocol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None